First-trimester risk calculation for trisomy 13, 18, and 21: comparison of the screening efficiency between 2 locally developed programs and commercial software
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
First-trimester risk calculation for trisomy 13, 18, and 21: comparison of the screening efficiency between 2 locally developed programs and commercial software. / Sørensen, Steen; Momsen, Günther; Sundberg, Karin; Friis-Hansen, Lennart; Jørgensen, Finn Stener.
In: Clinical Chemistry, Vol. 57, No. 7, 2011, p. 1023-31.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - First-trimester risk calculation for trisomy 13, 18, and 21: comparison of the screening efficiency between 2 locally developed programs and commercial software
AU - Sørensen, Steen
AU - Momsen, Günther
AU - Sundberg, Karin
AU - Friis-Hansen, Lennart
AU - Jørgensen, Finn Stener
PY - 2011
Y1 - 2011
N2 - Reliable individual risk calculation for trisomy (T) 13, 18, and 21 in first-trimester screening depends on good estimates of the medians for fetal nuchal translucency thickness (NT), free ß-subunit of human chorionic gonadotropin (hCGß), and pregnancy-associated plasma protein-A (PAPP-A) in maternal plasma from unaffected pregnancies. Means and SDs of these parameters in unaffected and affected pregnancies are used in the risk calculation program. Unfortunately, our commercial program for risk calculation (Astraia) did not allow use of local medians. We developed 2 alternative risk calculation programs to assess whether the screening efficacies for T13, T18, and T21 could be improved by using our locally estimated medians.
AB - Reliable individual risk calculation for trisomy (T) 13, 18, and 21 in first-trimester screening depends on good estimates of the medians for fetal nuchal translucency thickness (NT), free ß-subunit of human chorionic gonadotropin (hCGß), and pregnancy-associated plasma protein-A (PAPP-A) in maternal plasma from unaffected pregnancies. Means and SDs of these parameters in unaffected and affected pregnancies are used in the risk calculation program. Unfortunately, our commercial program for risk calculation (Astraia) did not allow use of local medians. We developed 2 alternative risk calculation programs to assess whether the screening efficacies for T13, T18, and T21 could be improved by using our locally estimated medians.
U2 - http://dx.doi.org/10.1373/clinchem.2010.161299
DO - http://dx.doi.org/10.1373/clinchem.2010.161299
M3 - Journal article
VL - 57
SP - 1023
EP - 1031
JO - Clinical Chemistry
JF - Clinical Chemistry
SN - 0009-9147
IS - 7
ER -
ID: 40167669